AKTUAPHARMA
ActiveSummary
The computed 12-month bankruptcy probability of AKTUAPHARMA is 3.2% (moderate). The 2025 annual accounts show negative equity (-€3.2m) and a net result of -€115,471. Equity is shrinking by ~2.7% per year across the filed fiscal years. The company has been active since 1998 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
No current score
Insufficient figures
A score requires measurable solvency, liquidity and profitability. Missing figures are not a judgement about the company.
Axes · tick = 2024
Profitability-
Solvency-
Growth32=
Track record100
Bankruptcy probability, 12 months
3.2%
Moderate
0%0.5%1.5%4%10%≥ 25%
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year -€3.2m
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
24 d early
2024
34 d early
2023
34 d early
2022
21 d early
2021
24 d early
2020
18 d early
2019
22 d early
← before the deadline
after the deadline →
tick = median of all Belgian filings
This company filed its last 7 accounts on average 25 days before the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 7 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven monthsPosition in the running window
29-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Is this your company? See how customers and banks see it.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2025, full schema
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€115,471▲ 24.7%
2024 · -€153,447
Working capital
-€2.8m▼ 1.5%
2021 · -€2.7m
Trend over the years
Click a name to add, emphasise or remove a line.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20212022202320242025
Operating result-€17,328▼ 188%-€12,971▲ 25.1%-€13,881▼ 7.0%-€13,816▲ 0.5%-€14,602▼ 5.7%
Net result-€43,770▼ 35.9%-€39,951▲ 8.7%-€123,418▼ 209%-€153,447▼ 24.3%-€115,471▲ 24.7%
Equity-€2.7m▼ 1.6%-€2.8m▼ 1.5%-€2.9m▼ 4.4%-€3.1m▼ 5.3%-€3.2m▼ 3.8%
Total assets€4,329▲ 3,574%€4,167▼ 3.7%
Debt€2.8m▲ 1.8%€2.8m▲ 1.4%€2.9m▲ 4.3%€3.1m▲ 5.3%€3.2m▲ 3.8%
Working capital-€2.7m▼ 1.6%-€2.8m▼ 1.5%
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €14,602 in 2025 against €13,816 in 2024; the loss grows.
Key figures and ratios
Debt to equity
-1.00=
2024 · -1.00
Debt ≤ 1 year
€3.2m▲
2024 · €3.1m
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Annual accounts
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Operating charges60/66A | €17,328 | €12,971 | €13,881 | €13,816 | €14,602 | ▲ 5.7% |
| Services and other goods61 | €17,328 | €12,971 | €13,881 | €13,816 | €14,057 | ▲ 1.7% |
| Non-recurring operating charges66A | - | - | - | - | €545 | - |
| Operating profit (loss)9901 | -€17,328 | -€12,971 | -€13,881 | -€13,816 | -€14,602 | ▼ 5.7% |
| Financial charges65/66B | €26,442 | €26,980 | €109,537 | €139,630 | €100,870 | ▼ 27.8% |
| Recurring financial charges65 | €26,442 | €26,980 | €109,537 | €139,630 | €100,870 | ▼ 27.8% |
| Debt charges650 | €25,540 | €25,907 | €108,700 | €138,841 | €100,181 | ▼ 27.8% |
| Other financial charges652/9 | €902 | €1,073 | €838 | €790 | €689 | ▼ 12.8% |
| Profit (loss) for the period before taxes9903 | -€43,770 | -€39,951 | -€123,418 | -€153,447 | -€115,471 | ▲ 24.7% |
| Profit (loss) for the period9904 | -€43,770 | -€39,951 | -€123,418 | -€153,447 | -€115,471 | ▲ 24.7% |
| Profit (loss) for the period to be appropriated9905 | -€43,770 | -€39,951 | -€123,418 | -€153,447 | -€115,471 | ▲ 24.7% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €4,329 | €4,167 | - | - | - | - |
| Current assets29/58 | €4,329 | €4,167 | - | - | - | - |
| Cash at bank and in hand54/58 | €4,329 | €4,167 | - | - | - | - |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €4,329 | €4,167 | €0 | €0 | €0 | - |
| Equity10/15 | -€2.7m | -€2.8m | -€2.9m | -€3.1m | -€3.2m | ▼ 3.8% |
| Contributions10/11 | €62,000 | €62,000 | €62,000 | €62,000 | €62,000 | = |
| Capital10 | €62,000 | €62,000 | €62,000 | €62,000 | €62,000 | = |
| Issued capital100 | €62,000 | €62,000 | €62,000 | €62,000 | €62,000 | = |
| Reserves13 | €1,866 | €1,867 | €1,867 | €1,867 | €1,867 | = |
| Non-distributable reserves130/1 | €1,866 | €1,867 | €1,867 | €1,867 | €1,867 | = |
| Legal reserve130 | €1,866 | €1,867 | €1,867 | €1,867 | - | - |
| Reserves not available under the articles1311 | - | - | - | - | €1,867 | - |
| Profit (loss) carried forward14 | -€2.8m | -€2.9m | -€3.0m | -€3.1m | -€3.2m | ▼ 3.7% |
| Amounts payable17/49 | €2.8m | €2.8m | €2.9m | €3.1m | €3.2m | ▲ 3.8% |
| Amounts payable within one year42/48 | €2.8m | €2.8m | €2.9m | €3.1m | €3.2m | ▲ 3.8% |
| Trade debts44 | €11,167 | €12,020 | €12,645 | €13,268 | €13,685 | ▲ 3.1% |
| Suppliers440/4 | €11,167 | €12,020 | €12,645 | €13,268 | €13,685 | ▲ 3.1% |
| Other amounts payable47/48 | €2.7m | €2.8m | €2.9m | €3.1m | €3.2m | ▲ 3.8% |
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€43,770 | -€39,951 | -€123,418 | -€153,447 | -€115,471 | ▲ 24.7% |
| Operating cash flow (approximation) | -€43,770 | -€39,951 | -€123,418 | -€153,447 | -€115,471 | ▲ 24.7% |
| Change in cash | - | -€162 | - | - | - | - |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
07-07
NBB filing
Annual accounts filed
fiscal year 2025 · full schema
02-07
State Gazette act
Resignations: DOCPHARMA BV, Viatris GX BV and Deloitte Bedrijfsrevisoren BVReappointments: DOCPHARMA BV, Viatris GX BV and Deloitte Bedrijfsrevisoren BV · Permanent representatives: Tomasz Buczek, Arun Narayan and Tom Renders10 facts ▸
State Gazette act
Resignations: DOCPHARMA BV, Viatris GX BV and Deloitte Bedrijfsrevisoren BV
Reappointments: DOCPHARMA BV, Viatris GX BV and Deloitte Bedrijfsrevisoren BV · Permanent representatives: Tomasz Buczek, Arun Narayan and Tom Renders10 facts ▸
- General meeting, 18-06-2026
- Director resignation, DOCPHARMA BV (managing director)
- Director resignation, Viatris GX BV (director)
- Director reappointment, DOCPHARMA BV (managing director)
- Director reappointment, Viatris GX BV (director)
- Permanent representative, Tomasz Buczek (permanent representative)
- Permanent representative, Arun Narayan (permanent representative)
- Auditor resignation, Deloitte Bedrijfsrevisoren BV (statutory auditor)
- Auditor reappointment, Deloitte Bedrijfsrevisoren BV (statutory auditor)
- Permanent representative, Tom Renders (permanent representative)
2025
10-12
State Gazette act
Permanent representative: Arun NarayanPower of attorney4 facts ▸
State Gazette act
Permanent representative: Arun Narayan
Power of attorney4 facts ▸
- Board meeting, 25-11-2025
- Permanent representative, Arun Narayan
- Power of attorney, Johan Lagae
- Power of attorney, Els Bruls
10-07
State Gazette act
Permanent representative: Tomasz Buczek2 facts ▸
State Gazette act
Permanent representative: Tomasz Buczek
2 facts ▸
- Board meeting, 23-06-2025
- Permanent representative, Tomasz Buczek
27-06
NBB filing
Annual accounts filed
fiscal year 2024 · full schema
2024
31-12
Financial
Weakest financial yearnet -€153,447
Net result drops to -€153,447, the lowest in the series; recovery starts the following year.
27-06
NBB filing
Annual accounts filed
fiscal year 2023 · full schema
21-03
State Gazette act
Permanent representative: Matthew Salzmann2 facts ▸
State Gazette act
Permanent representative: Matthew Salzmann
2 facts ▸
- Board meeting, 28-02-2024
- Permanent representative, Matthew Salzmann
15-02
State Gazette act
Statutes amendmentCapital4 facts ▸
State Gazette act
Statutes amendment
Capital4 facts ▸
- General meeting, 26-12-2023
- Statutes amendment
- Statutes amendment
- Capital, €62.000
2023
11-07
State Gazette act
Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)Permanent representative: Gert Vanhees · Power of attorney5 facts ▸
State Gazette act
Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)
Permanent representative: Gert Vanhees · Power of attorney5 facts ▸
- General meeting, 28-06-2023
- Auditor reappointment, Deloitte Bedrijfsrevisoren BV (statutory auditor)
- Permanent representative, Gert Vanhees
- Power of attorney, Johan Lagae
- Power of attorney, Els Bruls
10-07
NBB filing
Annual accounts filed
fiscal year 2022 · full schema
2022
07-07
NBB filing
Annual accounts filed
fiscal year 2021 · full schema
Show earlier events
2021
13-07
NBB filing
Annual accounts filed
fiscal year 2020 · full schema
10-05
State Gazette act
Permanent representative: L. BirbuetResignation: José Cotarelo (permanent representative)3 facts ▸
State Gazette act
Permanent representative: L. Birbuet
Resignation: José Cotarelo (permanent representative)3 facts ▸
- Board meeting, 31-03-2021
- Permanent representative, L. Birbuet (bestuurder bij aktuapharma)
- Director resignation, José Cotarelo (permanent representative)
2020
14-07
State Gazette act
Reappointments: Docpharma BV, Mylan BV and Deloitte BedrijfsrevisorenMandate compensation6 facts ▸
State Gazette act
Reappointments: Docpharma BV, Mylan BV and Deloitte Bedrijfsrevisoren
Mandate compensation6 facts ▸
- General meeting, 18-06-2020
- Director reappointment, Docpharma BV (director)
- Director reappointment, Mylan BV (director)
- Mandate compensation, Docpharma BV
- Mandate compensation, Mylan BV
- Auditor reappointment, Deloitte Bedrijfsrevisoren
09-07
NBB filing
Annual accounts filed
fiscal year 2019 · full schema
2019
09-07
NBB filing
Annual accounts filed
fiscal year 2018 · full schema
08-02
State Gazette act
Permanent representatives: José Cotarelo and Vincent Verschraegen3 facts ▸
State Gazette act
Permanent representatives: José Cotarelo and Vincent Verschraegen
3 facts ▸
- Board meeting, 20-12-2018
- Permanent representative, José Cotarelo
- Permanent representative, Vincent Verschraegen
2018
04-07
NBB filing
Annual accounts filed
fiscal year 2017 · full schema
2017
19-09
State Gazette act
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)2 facts ▸
State Gazette act
Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)
2 facts ▸
- General meeting, 30-08-2017
- Auditor reappointment, Deloitte Bedrijfsrevisoren
31-08
NBB filing
Annual accounts filed
fiscal year 2016 · full schema · 31 days late
26-04
State Gazette act
Permanent representatives: M. Von Wülfing and A. van 't Hullenaar3 facts ▸
State Gazette act
Permanent representatives: M. Von Wülfing and A. van 't Hullenaar
3 facts ▸
- Board meeting, 16-03-2017
- Permanent representative, M. Von Wülfing
- Permanent representative, A. van 't Hullenaar
2016
15-09
State Gazette act
Permanent representative: Jens Neuschaefer2 facts ▸
State Gazette act
Permanent representative: Jens Neuschaefer
2 facts ▸
- Board meeting, 30/08/2016
- Permanent representative, Jens Neuschaefer
02-05
State Gazette act
Permanent representative: Ivo D'Angelo2 facts ▸
State Gazette act
Permanent representative: Ivo D'Angelo
2 facts ▸
- Board meeting, 11-04-2016
- Permanent representative, Ivo D'Angelo
2015
25-09
State Gazette act
Permanent representatives: Yves Brigode and Jacek Glinka4 facts ▸
State Gazette act
Permanent representatives: Yves Brigode and Jacek Glinka
4 facts ▸
- Board meeting, 31-08-2015
- Permanent representative, Yves Brigode (permanent representative)
- Board meeting, 09-09-2015
- Permanent representative, Jacek Glinka (permanent representative)
29-01
State Gazette act
Resignation: Gary Sphar (director)Appointment: Mylan BVBA (director) · Mandate compensation · Power of attorney5 facts ▸
State Gazette act
Resignation: Gary Sphar (director)
Appointment: Mylan BVBA (director) · Mandate compensation · Power of attorney5 facts ▸
- General meeting, 31-12-2014
- Director resignation, Gary Sphar (director)
- Director appointment, Mylan BVBA (director)
- Mandate compensation, Mylan BVBA
- Power of attorney, Karen Laevaert
2014
23-07
State Gazette act
Reappointments: Docpharma BVBA (director) and Deloitte Bedrijfsrevisoren (statutory auditor)Mandate compensation · Power of attorney · Representation6 facts ▸
State Gazette act
Reappointments: Docpharma BVBA (director) and Deloitte Bedrijfsrevisoren (statutory auditor)
Mandate compensation · Power of attorney · Representation6 facts ▸
- General meeting, 19-06-2014
- Director reappointment, Docpharma BVBA (director)
- Mandate compensation, Docpharma BVBA
- Auditor reappointment, Deloitte Bedrijfsrevisoren
- Power of attorney, Karen Laevaert
- Representation, vertegenwoordigd door mevrouw Khadija Badli
13-02
State Gazette act
Permanent representative: Khadija Badli2 facts ▸
State Gazette act
Permanent representative: Khadija Badli
2 facts ▸
- Board meeting, 17-12-2013
- Permanent representative, Khadija Badli
2013
24-10
State Gazette act
Permanent representatives: Pascale Engelen and Steen VangsgaardPower of attorney4 facts ▸
State Gazette act
Permanent representatives: Pascale Engelen and Steen Vangsgaard
Power of attorney4 facts ▸
- Board meeting, 24-09-2013
- Permanent representative, Pascale Engelen
- Permanent representative, Steen Vangsgaard
- Power of attorney, Karen Laevaert
30-05
State Gazette act
Resignation: Kristin A Kolesar (director)Appointment: Gary Elmer SPHAR (director) · Mandate compensation4 facts ▸
State Gazette act
Resignation: Kristin A Kolesar (director)
Appointment: Gary Elmer SPHAR (director) · Mandate compensation4 facts ▸
- General meeting, 06-05-2013
- Director resignation, Kristin A Kolesar (director)
- Director appointment, Gary Elmer SPHAR (director)
- Mandate compensation, Gary Elmer SPHAR
2011
12-08
State Gazette act
Resignation: Seshan Srinivasan (director)Appointments: Kristin Ann KOLESAR (director) and Docpharma BVBA (afgevaardigd bestuurder) · Permanent representative: Pascale Engelen · Reappointment: Deloitte Bedrijfsrevisoren BV ovv CVBA (statutory auditor)10 facts ▸
State Gazette act
Resignation: Seshan Srinivasan (director)
Appointments: Kristin Ann KOLESAR (director) and Docpharma BVBA (afgevaardigd bestuurder) · Permanent representative: Pascale Engelen · Reappointment: Deloitte Bedrijfsrevisoren BV ovv CVBA (statutory auditor)10 facts ▸
- General meeting, 01-07-2011
- Director resignation, Seshan Srinivasan (director)
- Director appointment, Kristin Ann KOLESAR (director)
- Mandate compensation, Kristin Ann KOLESAR
- Board meeting, 08-07-2011
- Permanent representative, Pascale Engelen (permanent representative)
- Director appointment, Docpharma BVBA (afgevaardigd bestuurder)
- Mandate compensation, Docpharma BVBA
- General meeting, 20-07-2011
- Auditor reappointment, Deloitte Bedrijfsrevisoren BV ovv CVBA
2010
12-10
State Gazette act
Permanent representative: Vincent BouldoiresResignation: Prasad Nimmagadda (director) · Power of attorney4 facts ▸
State Gazette act
Permanent representative: Vincent Bouldoires
Resignation: Prasad Nimmagadda (director) · Power of attorney4 facts ▸
- Board meeting, 20-05-2010
- Permanent representative, Vincent Bouldoires
- Power of attorney, Vincent Bouldoires
- Director resignation, Prasad Nimmagadda
20-01
State Gazette act
Statutes amendment3 facts ▸
State Gazette act
Statutes amendment
3 facts ▸
- General meeting, 28-12-2009
- Statutes amendment
- Statutes amendment
08-01
State Gazette act
Registered officeRegistered-office move2 facts ▸
State Gazette act
Registered office
Registered-office move2 facts ▸
- Board meeting, 11-12-2009
- Registered-office move, Terhulpsesteenweg 6A, 1560 Hoeilaart
2006
18-09
State Gazette act
Resignation: Stijn Van Rompay (director)Appointment: SVR Invest BVBA (director) · Permanent representative: Stijn Van Rompay4 facts ▸
State Gazette act
Resignation: Stijn Van Rompay (director)
Appointment: SVR Invest BVBA (director) · Permanent representative: Stijn Van Rompay4 facts ▸
- General meeting, 18-11-2005
- Director resignation, Stijn Van Rompay (director)
- Director appointment, SVR Invest BVBA (director)
- Permanent representative, Stijn Van Rompay
15-05
State Gazette act
Capital & shares · Statutes amendment · RestructuringDemerger · Share issue · Accounting effect12 facts ▸
State Gazette act
Capital & shares · Statutes amendment · Restructuring
Demerger · Share issue · Accounting effect12 facts ▸
- General meeting, 30-03-2006
- Demerger, partial, Productie en Voorraadbeheer
- Share issue, new shares, 15431
- Accounting effect, 01-07-2005
- Capital decrease, €1.543.118,97
- Capital increase, €43.334,84
- Capital, €62.000
- Power of attorney, Laurent MEUR
- Power of attorney, Steven Peters
- Power of attorney, Koen Feyaerts
- Power of attorney, Elke Janssens
- Power of attorney, Jesse Verbist
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
25 of 25 acts read
Directors · office · real estate
Directors
3 directors, no change since 2026
Board 3
SVR Invest BVBA
Not recently confirmedDirector · since 18-11-2005 · Legal entity · perm. rep.: Stijn Van Rompay
Kristin Ann KOLESAR
Not recently confirmedDirector · since 01-07-2011
Gary Elmer SPHAR
Not recently confirmedDirector · since 06-05-2013
Day-to-day management 1
Docpharma BVBA
Not recently confirmedAfgevaardigd bestuurder · since 08-07-2011 · Legal entity · perm. rep.: Pascale Engelen
Permanent representatives 2
Stijn Van Rompay
Not recently confirmedPermanent representative · since 18-11-2005 · for SVR Invest BVBA
Pascale Engelen
Not recently confirmedPermanent representative · since 08-07-2011 · for Docpharma BVBA
Statutory auditor 1
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises
CurrentStatutory auditor · since 01-07-2011 · perm. rep.: Tom Renders
Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ.
See the function holders in the CBE →
Location & real-estate footprint
Registered office, Hoeilaart · 1 establishment unit since 1998
Ground area
3,821 m²
Building footprint
921 m²
Volume, LiDAR
10,579 m³
Parcel 23033C0075/00L019, Flanders · tallest building 14.7 m, ±4 floors. Linked by address, not a title deed.
6
companies at this address
See who is registered here
1 establishment unit
Terhulpsesteenweg 6A, 1560 Hoeilaart
since 19982.087.440.889
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23033C0075/00L019 | Flanders | 3,821 m² | 1 · 921 m² | 14.7 m · 4 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
13 people since 2005, 5 in office
- Board
- Day-to-day management
- Permanent representative
- Statutory auditor
- not recently confirmed
- began earlier
| Name | Functions and periods |
|---|---|
| Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises |
|
| SVR Invest BVBA |
|
| Kristin Ann KOLESAR |
|
| Gary Elmer SPHAR |
|
| Docpharma BVBA |
|
| DOCPHARMA |
|
| Viatris GX |
|
| Jose Cotarelo |
|
| Gary Sphar |
|
| Kristin A Kolesar |
|
| Seshan Srinivasan |
|
| Nimmagadda Prasad |
|
| Stijn Van Rompay |
|
Articles of association
Who signs
Each director alone
Purpose
Het zoeken naar nieuwe farmaceutische producten, het verbeteren van bestaande toonbankproducten en geneesmiddelen, het laten vervaardigen of zelf vervaardigen van deze producten…
Full purpose
Het zoeken naar nieuwe farmaceutische producten, het verbeteren van bestaande toonbankproducten en geneesmiddelen, het laten vervaardigen of zelf vervaardigen van deze producten, import en export van farmaceutische producten en aanverwanten, het commercialiseren op de Belgische en buitenlandse markt. De vennootschap heeft tot voorwerp het verrichten van alle diensten die rechtstreeks of onrechtstreeks met deze bedrijvigheid verband houden. Zij mag deelnemen, participeren of tussenkomen in andere ondernemingen of vennootschappen...
Board rule
Alle handelingen die nodig of dienstig zijn tot verwezenlijking van het voorwerp van de Vennootschap, bevoegdheid raad van bestuur
Structure & network
Owners and holdings
2 ownersChain of control
- Viatris GX
- DOCPHARMA
- AKTUAPHARMA
Highest known parent: Viatris GX. The sources do not say who stands above it.
Owners 2
- DOCPHARMAparent99.99%
-
0.01%
Holdings 0
The accounts to 31-12-2025 list no holdings, and no other source names one.
According to the 2025 annual accounts of AKTUAPHARMA and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.
Connections & network
1 connected companyThe connected companies are in the list below.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, scroll to zoom.
Linked via shared directors
ORTHOSPINE
Shared corporate director
→
Acquisitions and mergers
1 transactionSplit off to:VALUE PHARMA INTERNATIONAL
Capital and shareholders
Capital over the years
- 15-02-2024 Capital stated in the act · 62,000 EUR · 120,000 shares
- 15-05-2006 Capital reduction of 1,543,118.97 EUR
- 15-05-2006 Capital increase of 43,334.84 EUR · to 62,000 EUR · in cash
Identification & contact
Identification
Legal formPublic limited company
Founded16-06-1998
Fiscal year end31-12
E-invoicing
Reachable via Peppol
Peppol ID
0208:0463582004
Also
9925:BE0463582004
Registered
20-11-2020
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 29 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.